Kornimate/medical-research-clean huggingface dataset:
testing the effect of crustacean's gastrolith nutraceutical on mineralization rate during distraction osteogenesis

Conditions: Skeletal Deformities; Leg Length Discrepancy

Summary: background: distraction osteogenesis, the gradual lengthening of bones, is performed in order to equalize leg length discrepancy and correct skeletal deformities or to achieve greater height in short stature people. the femur and tibia are the bones most frequently lengthened. the surgery is currently performed at hadassah medical center routinely by the pediatric orthopedic team utilizing a variety of external fixation devices. the procedure involves application of an external fixation device to the bone, creation of an osteotomy and gradual, controlled distraction of the bone fragments on the last week of the distraction phase and every month thereafter, patients will be provided with a monthly supply of gastrolith calcium in a sealed container (65 capsules of 500 mg each, provided by amorphical). starting on the first day of the last week of the distraction phase, during the entire consolidation phase until the external fixator is removed; adults will orally consume two (2) 500 mg capsules a day (total of 1 gr of gastrolith calcium). children will be given 25 mg calcium per kg body weight up to the daily adult dose of 1000mg .


Eligibility criteria:
inclusion criteria: 1. males and females 2. ages 4-30 years old. exclusion criteria: 1. product allergy 2. refusal to participate the study. 3. metabolic disorders

Keywords: distraction osteogenesis
flap sliding to treat post-lasik striae

Conditions: LASIK Complication Management

Summary: this study assessed the efficacy and safety of a simple, noninvasive "flap sliding" technique for managing flap striae following laser in situ keratomileusis (lasik). included eyes underwent flap sliding 1-2 days after surgery, which involved using a cellulose sponge to gently slide the flap perpendicular to the striae. the flap was not lifted during the procedure. thirteen of 14 eyes were successfully managed with flap sliding. uncorrected distance visual acuity (dva) improved in all patients 1 day after flap sliding, with 11 eyes having a corrected dva of 20/25 or better. complications following flap sliding occurred in 2 eyes. we believe that our study makes a significant contribution to the literature because it demonstrates a simple, noninvasive technique for managing flap striae that develop during early post-lasik epithelial healing.


Eligibility criteria:
inclusion criteria: significant flap striae in the visual zone within 2 days following microkeratome lasik. exclusion criteria: * striae 2 days after surgery * visually insignificant striae
safety and efficacy of alteplase when administered in chinese patients with acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4.5 hours after stroke onset

Conditions: Stroke

Summary: to evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in chinese patients with acute ischemic stroke


Eligibility criteria:
inclusion criteria: age \>= 18 years at screening(visit 1a) but \<= 80 years signed and dated written informed consent in accordance with good clinical practice and local legislation prior to admission to the trial diagnosis of ischemic stroke with a measureable neurological deficit on national institute of health stroke scale (nihss) thrombolytic therapy can be initiated within 3 to 4.5 hours of stroke onset further inclusion criteria apply exclusion criteria: evidence of intracranial haemorrhage (ich) on the (computer tomography) ct/(magnetic resonance imaging)mri-scan or symptoms suggestive of subarachnoid haemorrhage, even if the ct/mri-scan is normal acute bleeding diathesis severe stroke as assessed clinically( e.g. national institute of health stroke scale\>25) and/ or imaging demonstrates multi-lobar infarction (hypodensity \>1/3 cerebral hemisphere) severe uncontrolled arterial hypertension, e.g. systolic blood pressure\>185 mmhg or diastolic blood pressure\>110mmhg, or aggressive management (intravenous medication) necessary to reduce blood pressure to these limits blood glucose \ 400 mg/dl any history of prior stroke in previous 3 months, or any history of prior stroke with concomitant diabetes seizure at stroke onset further exclusion criteria apply
explore the associations of behavioral factors with treatment adherence in axial spondyloarthritis patients treated with biotherapy.

Conditions: Axial Spondyloarthritis

Summary: the management of chronic inflammatory rheumatism, including spondyloarthritis (spa), has been revolutionized in recent decades with the arrival of biological therapy. the success of the current therapeutic strategy is also based on therapeutic compliance. if therapeutic adherence in rheumatoid arthritis patient (ra) is only 66%, it seems even worse in spa. few studies report quantitatively the adherence of spa patients, as well as the predictive or associated factors. the objective of this study is to assess the patient adherence to biologics in patients with axial spa (spaax), and to investigate factors influencing this adherence, in particular the association with vaccination coverage, dietary behavior, and digital health tools.

multicentric cross-sectional survey of patients seen in the context of a rheumatology consultation or hospitalization. on the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing spaax follow-up to assess their compliance with biologic drugs, their vaccination coverage, their diet, the presence of a fibromyalgia syndrome or inflammatory bowel disease, intestinal disorders, regular physical activity and sedentary lifestyle, the frequency and mode of use of mobile applications and/or connected objects related to health, the presence of catastrophic thoughts and the presence of anxiety and depressive disorders. medical data relevant to routine care will be collected.(age, sex, weight, height, tobacco and alcohol use, disease characteristics, spa treatment, comorbidities)

Eligibility criteria:
inclusion criteria: * patient \>18 years old with axial spondyloarthritis according to asas criteria and treated with biotherapy. * french-speaking, without any understanding problems. exclusion criteria: * patients under curatorship, guardianship or other legal protection * patients refusing to consent to participate in research * pregnant and breastfeeding women.

Keywords: adherence biologic treatment spondyloarthritis
cardiopulmonary outcomes in osteogenesis imperfecta: bbd7708

Conditions: Osteogenesis Imperfecta

Summary: osteogenesis imperfecta (oi) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the united states. oi varies in severity from perinatally lethal to mild forms. the majority of cases is caused by a dominant mutation in type i collagen genes (col1α1 and col1α2), altering the quantity or quality of type i collagen. although oi is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. type i collagen is a major constituent of lung connective tissue. respiratory insufficiency is the leading cause of death in patients with oi. thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the oi population.

this study is cross-sectional. at the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. eighteen participants will be enrolled, ideally within one year. participants will be enrolled regardless of oi type since bronchial wall thickening, a finding we are attempting to validate, was observed in all types of oi. interested males with oi will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with oi. smokers will not be excluded.

Eligibility criteria:
inclusion criteria: * individuals who are able to give informed consent or have a legally authorized representative capable of giving consent on the subject's behalf * individuals ages 18 and older of all races and sexes * individuals who have been diagnosed with oi clinically and/or genetically exclusion criteria: * individuals diagnosed with respiratory illness within 6 weeks of enrollment or undergoing diagnostic studies for an active illness. * individuals with other skeletal dysplasia or genetic diagnosis * individuals diagnosed with cardiopulmonary comorbidities that affect lung compliance
deep learning models for prediction of intraoperative hypotension using non-invasive parameters

Conditions: Intraoperative Hypotension; General Anesthesia

Summary: the investigators aimed to investigate the deep learning model to predict intraoperative hypotension using non-invasive monitoring parameters.

intraoperative hypotension is associated with various postoperative complications such as acute kidney injury. therefore, precise prediction and prompt treatment of intraoperative hypotension are important. however, it is difficult to accurately predict intraoperative hypotension based on the anesthesiologists' experience and intuition. recently, deep learning algorithms using invasive arterial pressure monitoring showed the good predictive ability of intraoperative hypotension. it can help the clinician's decisions. however, most patients undergoing general surgery are monitored by non-invasive parameters. therefore, the investigators investigate the prediction model for intraoperative hypotension using non-invasive monitoring.

Eligibility criteria:
inclusion criteria: * the patients who are included in the open database, vtialdb. * the patients who underwent inhaled general anesthesia for non-cardiac surgery. * the patients who have non-invasive monitoring data including blood pressure, electrocardiography, pulse oximetry, bispectral index, and capnography. exclusion criteria: * the patient with missing data.

Keywords: intraoperative hypotension noninvasive monitor deep learning algorithm
sevoflurane in subarachnoidal haemorrhage

Conditions: Subarachnoid Haemorrhage (SAH)

Summary: feasibility and safety of short term application of sevoflurane in patients with sah treated with aneurysm coiling or clipping in the setting of a neurointensive care unit.

after admission to the icu, before the coiling / clipping intervention has been performed, the patients are screened for eligibility. when the patients are coming back to the icu, after successful aneurysm coiling or clipping, data of artificial ventilation, systemic and other cerebral parameters will be collected continuously by online monitoring, starting at baseline and stopping at discharge of the icu. sevoflurane will be vaporized and administrated by the mirus™system directly to the inspiratory part of the ventilation circuit for the next 4 hours. in the following 14 days of the stay on the icu, standard monitoring parameters, the appearance of vasospasm and brain oedema will be recorded. besides the continuous online monitoring, laboratory assessment will be performed daily. at day 7±2 and day 14±2 after bleeding a mri or ct examination will be performed, according to the clinical condition of the patient, to detect secondary brain injuries, as ischemia or brain oedema. at icu discharge, the neurological outcome will be assesses applying gos.

Eligibility criteria:
inclusion criteria: * patients of either sex aged 18-85 years * patients with severe aneurysmal sah, hunt/hess 3 to 5. * the ruptured aneurysm is successfully excluded with coiling or clipping * sedation and mechanical ventilation necessary due to the clinical situation * icp monitoring in use due to the clinical situation * icp \< 20mmhg without medical treatment * systolic blood pressure values (bp syst) \> 120 mmhg with no need for catecholamines * female patients of childbearing potential with negative pre-treatment serum pregnancy test * informed consent obtained exclusion criteria: * significant kidney disease, defined as plasma creatinine \>120 µmol/l * significant liver disease, defined as aspartate-aminotransferase (ast) \>200 u/l * significant elongation of the qtc interval: female \< 470 msec/ male \< 450 msec; based on 'bazett's formula' * history of epilepsia and/ or occurring seizures with aneurysm rupture * pneumocephalus after surgery excluded by ct scan performed immediately after clipping * history of allergic disorders * history for, or relatives with a history for malignant hyperthermia * history or signs for neuromuscular disease * pre-existing disability * patients participating in an interventional clinical trial within the last 30 days before start of treatment

Keywords: severe sah prevention of vasospasm and/ or brain oedema sevoflurane postconditioning
intensive short-term dynamic psychotherapy (istdp) for anxiety diagnoses in a primary care setting

Conditions: Psychotherapy; Anxiety Disorders; Psychiatric &or Mood Disorder

Summary: living with anxiety often means great suffering for the person affected. the trend points to a continued increase in anxiety problems in the population, especially in the 18-44 age group. inadequate treatment of this condition can lead to long-term sick leave, isolation, exclusion and, in the worst case, to death. the treatment methods that are available in primary care today help some but far from all. therefore, the investigators want to scientifically evaluate a shorter version of a proven emotion-focused psychotherapy in order to increase the treatment range for this patient group. the aim of this project is to, in a primary care setting, test and evaluate an intensive, emotion-focused short-term therapy, istdp (intensive short-term dynamic psychotherapy) for patients with an anxiety diagnosis. the method is well-proven on patients with more severe mental conditions (personality disorders) with good results, but the treatment has only been tested to a limited extent on patients with anxiety symptoms. the investigators want to investigate the effectiveness of treating various anxiety states for primary care patients. the treatment is expected to provide an addition to today's methods, which overall will provide better treatment results for this, increasing in number, group of patients who often seek primary care.


Eligibility criteria:
inclusion criteria: * primary care patients with primary anxiety diagnoses at a health care clinic in sweden. sufficient language competence in swedish is required of the participants to understand, read, speak and write. exclusion criteria: * major reading-writing and learning difficulties, severe psychiatric problems such as psychosis, eating disorder, current major depression, recurrent depression, severe trauma, acute crisis reaction, exhaustion, acute risk of suicide (assessed according to the suicide scale), addiction. * diagnosed specific phobia or obsessive-compulsive disorder that must be primarily treated with cbt. concurrent psychological treatment, anxiety-relieving medication such as benzodiazepines, or recently started antidepressant treatment (\< 3 months of treatment) are also exclusion criteria for participation in the study.

Keywords: anxiety disorders primary care setting psychotherapy clinical research
tumor lysate pulsed dendritic cell immunotherapy for patients with brain tumors

Conditions: Glioblastoma

Summary: this research is being determine whether vaccinations with your own immune cells called " dendritic cells " can activate your immune system to fight your brain tumor.

to become eligible for therapy the following criteria must be fulfilled: * no age or gender limit * patients with atypical malignant brain tumors. * must have a karnofsky performance of at least 60% * hematologic studies and chemistry profiles will be within the parameters of the protocol * tumor specimen of adequate size to yield protein concentration, tumor lysate peptide must be generated in sufficient quantity and patient must have no prior sensitivity to the components of the dendritic cell vaccine. * patients are excluded if they have systemic disease, presence of acute infection, known history of autoimmune disorder and pregnancy.

Eligibility criteria:
inclusion criteria: * no age or gender limit, though minimal weight limitations for apheresis is about 15 - 20 kg. * both male and female of childbearing age entering the protocol must use a medically accepted form of birth control during the study, will be required to have a negative pregnancy test for female. * patients with atypical malignant brain tumor will be eligible. * patients must have a karnofsky performance score of at least 60% * patients may be maintained on glucocorticoid therapy at the lowest possible dose. * baseline hematologic studies and chemistry profiles must meet the criteria. * tumor specimen of adequate size to yield protein concentration in sufficient quantity. * tumor-lysate peptide must be generated in sufficient quantity to pulse the apc's for vaccination. * patient must have no prior sensitivity to the components of the dendritic cell vaccine. * patient must agree to consider an autopsy in the event of death in an attempt to learn more concerning the nature of this treatment and tumor biology. * patient must be capable of signing irb approved research consent and release of medical records form. exclusion criteria: * severe pulmonary, cardiac or other systemic disease associated with an unacceptable anesthetic or operative risk. * the presence of an acute infection requiring active treatment will be criteria for delay or exclusion. * patients with a known history of an autoimmune disorder. * inability to give informed consent. * pregnancy.

Keywords: new/recurrent glioblastoma
cm treatment for alcohol dependence using new technology

Conditions: Alcohol Use Disorder; Contingency Management

Summary: contingency management (cm) is highly efficacious for reducing substance use, and recent data suggest that reinforcing attendance at treatment can significantly improve treatment outcomes. importantly, cm interventions that reinforce attendance are more likely to be adopted clinically than those that reinforce abstinence. having objective indicators of drinking outcomes, nevertheless, is critical for quantifying the benefits of attendance-based cm treatment in alcohol abusing populations. new technology is now available to gauge alcohol use in patients' natural environments. the secure continuous remote alcohol monitor (scramx®) continuously monitors alcohol consumption 24 hours a day. as such, it may be ideal for objective evaluation of alcohol consumption during treatment intervention studies, including those that involve cm. in this study, 114 patients participating in community based outpatient treatment programs for alcohol use disorders will wear scramx for a 12-week period. they will be randomized to standard care or standard care plus cm, with reinforcement contingent upon attendance at treatment. the investigators will assess treatment attendance and alcohol use via scramx and self reports. the investigators expect that patients randomized to the cm intervention will remain in treatment longer and show reductions in both scramx assessed and self reported drinking days relative to those randomized to standard care.


Eligibility criteria:
inclusion criteria: * age 18 years or older * current diagnosis of alcohol use disorder * able to pass an informed consent quiz * agree to wear a scramx monitor for 12 weeks * have a standard, scramx compatible phone line in their home or agree to attend the clinic at least every other week for data downloads * agree to sign an off-campus property transfer form and return scramx equipment in 12 weeks exclusion criteria: * serious, uncontrolled psychiatric illness * in recovery from pathological gambling * unstable address * intend to participate in activities incompatible with scramx in the next 3 months * are wearing scramx for legal purposes
management of major trauma patients at aarau trauma center - evaluation of processes and patient outcome

Conditions: Injury; Trauma; Major Trauma; Multiple Trauma

Summary: quality control and improvement project: assessment and analysis of processes and outcome in trauma emergency room and major trauma patients at the aarau trauma center (cantonal hospital) with regard to initial emergency management, hospital processes and short- and long-term (1-and 2-year) outcome of patients (subjective and objective). comparison of processes and outcome pre- and post- project initiative. benchmarking with the literature and by participation in the german and swiss trauma registry each.

registry of all emergency patients arriving at aarau trauma center following trauma with regard to possibly injury related pre- and inhospital demographic factors, process variables and outcome parameters.

Eligibility criteria:
inclusion criteria: * major trauma: new injury severity score (niss) \>=8 * for longer-term outcome: only patients firm in german language and able to respond to the postal questionnaire by themselves exclusion criteria: * no trauma * injury \>24h before arrival at aarau cantonal hospital * niss\<8 * for longer-term outcome: patients not firm in german language and not able to respond to the postal questionnaire by themselves (dead, unavailable, refusal to participate, dementia, age\<16 years ecc.); a categorising compilation of cases is supposed to exclude any possible study bias

Keywords: trauma major trauma multiple trauma outcome quality process management emergency room trauma center
acute upper respiratory tract infection - when is bacteria involved?

Conditions: Acute Upper Respiratory Tract Infection and Acute Bacterial Rhinosinusitis

Summary: the purpose of this study is to find out if we can predict the progress of acute upper respiratory tract infection to acute bacterial rhinosinusitis in finnish conscripts by symptoms, clinical, endoscopic or radiological findings, middle meatal swab samples or nitric oxide measurement.

we will recruit conscripts with upper respiratory tract infection (common cold) during a two month period. we will recruit non-allergic conscripts. these conscripts should either have not had history of recurrent abr or they should have experienced recurrent acute (abr) bacterial rhinosinusitis at least 3 times during the last two years (diagnosed by a doctor and at least one time with x-ray or sinus puncture). the recruits will keep a record of their symptoms. they will be examined by a doctor soon after the symptoms have started (2-4 days) and when the symptoms have lasted about 7-10 days. clinical examination, nasal endoscopy and ultrasonographic examination of the maxillary sinuses are made, middle meatal specimen for bacteria and bacteria-pcr are taken, virus-pcr samples are taken from the nostril and nasopharynx, nitric oxide-measurements from both nasal cavities are recorded. cone beam ct of the maxillary and ethmoidal sinuses is made during the first examination, 2-4 days later and during the last examination. if the last ct-scan shows any other radiological signs than mild mucosal oedema in either maxillary sinus, maxillar sinus puncture is made and secretion is aspirated for culture and pcr. biopsy from the mucosa of nasal cavity (middle meatal area) is taken to examine the cilia and possible bacteria biofilm.

Eligibility criteria:
inclusion criteria: * conscript with acute upper respiratory tract infection symptoms (nasal obstruction/decongestion, post nasal drip or nasal secretion) lasted for 2-4 days exclusion criteria: * allergy, asthma, nasal polyposis, sinus surgery, autoimmune illness

Keywords: acute respiratory tract infection common cold acute bacterial rhinosinusitis adult conscript